FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 275 filers reported holding FATE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.99 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $100,700 | +127.5% | 47,500 | +410.8% | 0.01% | +133.3% |
| Q2 2023 | $44,268 | +3783.2% | 9,300 | +4550.0% | 0.00% | – |
| Q1 2023 | $1,140 | -99.6% | 200 | -99.3% | 0.00% | -100.0% |
| Q4 2022 | $273,439 | +296.3% | 27,100 | +774.2% | 0.02% | +300.0% |
| Q3 2022 | $69,000 | -89.2% | 3,100 | -71.3% | 0.01% | -89.4% |
| Q3 2021 | $641,000 | +2110.3% | 10,818 | +3119.6% | 0.05% | +2250.0% |
| Q2 2021 | $29,000 | +93.3% | 336 | +75.0% | 0.00% | +100.0% |
| Q1 2021 | $15,000 | 0.0% | 192 | +12.3% | 0.00% | -50.0% |
| Q4 2020 | $15,000 | -57.1% | 171 | -80.7% | 0.00% | -50.0% |
| Q3 2020 | $35,000 | -51.4% | 885 | -76.1% | 0.00% | -42.9% |
| Q4 2019 | $72,000 | +1700.0% | 3,700 | +1133.3% | 0.01% | – |
| Q3 2019 | $4,000 | – | 300 | +305.4% | 0.00% | – |
| Q2 2018 | $0 | -100.0% | 74 | -99.3% | 0.00% | -100.0% |
| Q1 2018 | $107,000 | – | 10,984 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |